Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Mease discussed the latest updates on apremilast and growing attention to cardiometabolic outcomes at ACR Convergence 2025.

Targeting Cardiometabolic Burden in PsA, With Philip Mease, MD

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

Deucravacitinib, Zasocitinib Validate TYK2 Inhibition in PsA, With Philip Mease, MD

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

At the SDPA Fall Conference, Singla speaks in an interview regarding screening patients with psoriasis for psoriatic arthritis (PsA).

How Often Should You Screen Patients with Psoriasis for PsA? With Shikha Singla, MD

Explore the complexities of psoriatic arthritis, its symptoms, and the importance of multidisciplinary management for effective treatment.

How to Differentiate Other Forms of Arthritis and Psoriatic Arthritis, With Shikha Singla, MD

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

7 Rheumatology Headlines You Missed in October 2025

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Achieving “State Zero”: New Data on Bimekizumab, Other IL-17is, Transform PsA Treatment Goals, with Philip Mease, MD

Switching to an IL-17 inhibitor after TNF inhibitor failure showed no superior benefits for axial spondyloarthritis.

ROC-SpA: IL-17i Not Superior to Cycling TNFi Post-Failure in AxSpA

Behrens discussed strong data supporting secukinumab's use over ustekinumab post-TNF inhibitor in PsA.

AgAIN: Secukinumab Outperforms Ustekinumab in Post-TNFi Psoriatic Arthritis, With Frank Behrens, MD

In long-term follow-up of KEEPsAKE 1 and 2, risankizumab maintained joint, skin, pain, and axial responses in patients with PsA through 244 weeks.

Risankizumab Maintains PsA Disease Control Through 5 Years in KEEPsAKE 1 & 2 Trials

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.